natgillin/translations-raw huggingface dataset:
Both cytochromes P450-2D6 and 1A2 catalyse the formation of the two major metabolites glucuronide conjugate of 4-hydroxy duloxetine and sulfate conjugate of 5-hydroxy 6-methoxy duloxetine.
Tako CYP2D6 kot tudi CYP1A2 katalizirata tvorbo dveh poglavitnih presnovkov glukuronidnega konjugata 4- hidroksi duloksetina in sulfatnega konjugata 5-hidroksi 6-metoksi duloksetina.
Both daily and intermittent (with prolonged dose-free intervals) long-term administration in rats, dogs and monkeys was associated with formation of new bone of normal quality and maintained or increased mechanical strength even at doses in the toxic range.
Tako dnevno kot intermitentno (s podaljšanimi premori brez odmerkov) dolgotrajno dajanje zdravila podganam, psom in opicam je bilo povezano s tvorbo nove kosti normalne kakovosti, mehanska moč pa je bila ohranjena ali celo povečana tudi pri toksičnih odmerkih.
Both diabetic ketoacidosis and hyperosmolar hyperglycaemia have been described, which generally respond to administration of exogenous insulin.
Opisani sta bili diabetična ketoacidoza in hiperosmolarna hiperglikemija, ki se običajno odzoveta na uporabo eksogenega insulina.
Both dose strengths of dabigatran etexilate had also a statistically significant lower total bleed rate.
Pri obeh jakostih dabigatran eteksilata je bil statistično značilno manjši tudi odstotek vseh krvavitev.
Both drugs are CYP3A4 inhibitors and may increase the plasma concentration of saquinavir.
Obe zdravili sta zaviralca CYP3A4 in lahko povečata koncentracijo sakvinavirja v plazmi.
Both emtricitabine and tenofovir work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses.
Emtricitabin in tenofovir na podoben način zavirata aktivnost reverzne transkriptaze, tj. encima, ki ga tvori virus HIV, s katerim lahko ta okuži celice ter tvori še več virusov.
Both endothelial cell damage and prothrombotic-hypofibrinolytic state are critical factors in the pathophysiology of this disease.
Poškodba endotelijskih celic in protrombotično-hipofibrinolitično stanje sta ključna dejavnika pri patofiziologiji te bolezni.
Both EXUBERA and comparator treated subjects experienced declines in lung function over time during these trials (Figures 2 and 3).
Tako pri bolnikih, zdravljenih z zdravilom EXUBERA, kot pri bolnikih, zdravljenih s primerjalnim zdravilom, se je med temi preskušanji sčasoma zmanjšala pljučna funkcija (sliki 2 in 3).
Both female and male patients must take special precautions in their sexual activity if there is any possibility for pregnancy to occur:
Tako bolnice kot bolniki morajo biti posebno previdni pri spolni aktivnosti, če obstaja možnost, da pride do nosečnosti:
Both groups had off periods of about 36-37% at the start of the study.
Pri obeh skupinah je ta delež na začetku študije znašal približno 36–37 %.
Both groups of medicines could influence the results of the Helicobacter Test INFAI for children of the age 3-11.
Obe skupini zdravil lahko vplivata na izid testa z zdravilom Test Helicobacter INFAI za otroke od 3 do 11 let.
Both groups showed a robust response to the booster dose of Menveo at one month after vaccination (100% of subjects had hSBA ≥ 1:8 across serogroups) and this response largely persisted through 2 years after the booster dose for serogroups C, W135 and Y (with 87% to 100% of subjects with hSBA ≥ 1:8 across serogroups).
V obeh skupinah je bil odziv na poživitveni odmerek cepiva Menveo zanesljiv po enem mesecu po cepljenju (pri 100 % oseb je bil hSBA ≥ 1:8 za vse seroskupine); ta odziv je pri seroskupinah C, W135 in Y (87 % do 100 % oseb s hSBA ≥ 1:8 v vseh skupinah) večinoma ostal tudi 2 leti po poživitvenem odmerku.
Both hoarseness and incidence of mouth and throat candidiasis may be relieved by rinsing the mouth with water and spitting the water out and/or brushing the teeth after using the product.
Tako hripavost kot pojavnost kandidoze ustne votline je možno ublažiti s splakovanjem ustne votline z vodo, ki jo nato bolnik izpljune, in/ali ščetkanjem zob po uporabi zdravila.
Both hoarseness and the incidence of candidiasis of the mouth and throat may be relieved by rinsing the mouth with water and spitting the water out and/or brushing the teeth after using the product.
Tako hripavost kot pojavnost kandidoze ustne votline in žrela je možno ublažiti s splakovanjem ustne votline z vodo, ki jo nato bolnik izpljune, in/ali ščetkanjem zob po uporabi zdravila.
Both hypoglycaemia and hyperglycaemia, which can occur in inadequately controlled diabetes therapy, increase the risk of malformations and death in utero.
Med nezadostno urejenim zdravljenjem diabetesa se lahko pojavita hipoglikemija in hiperglikemija, ki obe zvecujeta tveganje za malformacije in smrt in utero.
Both hypoglycaemia and hyperglycaemia, which can occur in inadequately controlled diabetes therapy, increase the risk of malformations and death in utero.
Zaradi neustrezno urejene sladkorne bolezni se lahko pojavi hipoglikemija ali hiperglikemija.
Both in healthy subjects and PAH patients, exposure at steady state to the active metabolite is approximately 3- to 4-fold higher than to the parent compound.
Tako pri zdravih osebah kot pri bolnikih s PAH je izpostavljenost aktivnemu presnovku v stanju dinamičnega ravnovesja približno 3- do 4-krat večja, kot izpostavljenost izhodni snovi.
Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been observed following exposure to toremifene, in the form of QT prolongation.
Po izpostavljenosti toremifenu so bile tako v predkliničnih raziskavah kot v raziskavah pri ljudeh opažene spremembe v elektrofiziologiji srca, in sicer v obliki podaljšanega intervala QT.
Both male and female patients should take adequate contraceptive measures up to three months after the discontinuation of the therapy.
Moški in ženske morajo uporabljati primerno kontracepcijo še tri mesece po prekinitvi zdravljenja.
Both medicinal products are metabolised intracellularly to their active moieties, lamivudine 5’-triphosphate (TP) and zidovudine 5’-TP respectively.
Obe zdravili se znotrajcelično presnavljata v svoji aktivni obliki, lamivudin 5'-trifosfat (TP) oziroma zidovudin 5'-TP.
Both medicines produced a cure in about 94% of patients (353 out of 375 given Zerbaxa and 375 out of 399 given meropenem).
Obe zdravili sta ozdravili približno 94 % bolnikov (353 od 375, ki so prejemali zdravilo Zerbaxa, in 375 od 399, ki so prejemali meropenem).
Both medicines were given as one drop in the affected eye once a day, in the evening.
Odmerki obeh zdravil so bili po ena kapljica v prizadeto oko enkrat dnevno, zvečer.
Both medicines were given in combination with daily prednisone or prednisolone.
Obe zdravili so dajali v kombinaciji z dnevnim odmerkom prednizona ali prednizolona.
Both medicines were taken in combination with didanosine and efavirenz (other antiviral medicines).
Bolniki so obe zdravili jemali v kombinaciji z didanozinom in efavirenzom (drugi vrsti protivirusnih zdravil).
Both metabolites, are further metabolised forming a common hydroxylated acid.
Oba presnovka se nadalje presnavljata v skupno hidroksilirano kislino.
Both metabolites, M-2 and M-5, exhibit non-linear accumulation, which might be caused by entero- hepatic recycling or saturation of the UGT1A9 pathway.
Oba presnovka, M-2 in M-5, se kopičita nelinearno, kar je lahko posledica enterohepatičnega kroženja ali nasičenja presnovne poti UGT1A9.
Both might interfere with the Helicobacter pylori status.
Obe skupini zdravil lahko vplivata na status Helicobacter pylori.
Both nucleoside and nucleotide reverse transcriptase inhibitors are commonly known as NRTIs.
Zaviralci nukleozidne in nukleotidne reverzne transkriptaze so znani pod skupnim imenom NRTI.
Both of these active ingredients can cause a serious allergic reaction known as a hypersensitivity reaction, which can be life threatening in people who continue to take abacavir-containing products.
Obe navedeni zdravilni učinkovini lahko povzročita hudo alergijsko reakcijo, tako imenovano preobčutljivostno reakcijo, ki je lahko življenjsko nevarna za tiste, ki še naprej jemljejo zdravila, ki vsebujejo abakavir.
Both of these active substances are antiretroviral medicines which are used to treat HIV infection.
Obe zdravilni učinkovini sta protiretrovirusni zdravili, ki se uporabljata za zdravljenje okužbe z virusom HIV.
Both patient populations presented a median age of 63 years, with a comparable male to female ratio.
Mediana starost je bila v obeh populacijah bolnikov 63 let, s primerljivim razmerjem moških in žensk.
Both patient populations presented a median age of 68.5 years with comparable male to female ratio.
Mediana starosti obeh populacij bolnikov je bila 68,5 let s primerljivim razmerjem med moškimi in ženskami.
Both patients recovered fully with symptomatic treatment.
Oba bolnika sta si povsem opomogla po zdravljenju simptomov.
Both piperaquine and artenimol are highly bound to human plasma proteins: the protein binding observed in in vitro studies was 44-93% for artenimol and >99% for piperaquine.
Tako piperakin kot artenimol se močno vežeta na beljakovine v človeški plazmi: vezava na beljakovine, ki so jo opazili v študijah in vitro, je bila 44–93 % za artenimol in > 99 % za piperakin.
Both pre-filled pens, the Liprolog 100 units/ml KwikPen and the Liprolog 200 units/ml KwikPen deliver 1 – 60 units in steps of 1 unit in a single injection.
Oba napolnjena injekcijska peresnika, Liprolog 100 enot/ml KwikPen in Liprolog 200 enot/ml KwikPen dostavita od 1 do 60 enot v korakih po 1 enoto v enkratnem injiciranju.
Both regimens were administered once every 3 weeks for 6 cycles.
Oba režima so aplicirali v 6 ciklih, enkrat na 3 tedne.
Both regimens were administered once every 3 weeks for 6 cycles.
Obe shemi so dajali enkrat na 3 tedne 6 ciklov.
Both regimens were well- tolerated by these patients.
Ti bolniki so obe shemi dobro prenašali.
Both residual and additional segments may be treated in the same light session(s) if the total length of the segments treated with the balloon/diffuser combination is not greater than 7 cm.
Tako preostali, kot dodatni segmenti, se lahko zdravijo s svetlobo v času istih obiskov, če celotna dolžina segmentov, zdravljenih s kombinacijo balona/difuzorja, ni večja od 7 cm.
Both saxagliptin and dapagliflozin can individually increase the risk of hypoglycaemia when combined with an insulin secretagogue.
Tako saksagliptin kot dapagliflozin lahko vsak zase povečata tveganje za hipoglikemijo, če sta uporabljena v kombinaciji s kakšnim insulinskim sekretagogom.
Both sexually active men and women of childbearing potential should use effective methods of contraception during treatment.
Med zdravljenjem morajo spolno aktivni moški in ženske v rodni dobi uporabljati učinkovito kontracepcijo.
Both sexually active men and women should use effective methods of contraception during treatment and for at least three months following cessation of treatment.
Spolno aktivne ženske in moški morajo med zdravljenjem in še najmanj tri mesece po končanem zdravljenju uporabljati učinkovito metodo kontracepcije.
Both sofosbuvir and velpatasvir were fully active against substitutions associated with resistance to other classes of direct acting antivirals with different mechanisms of actions, such as NS5B non-nucleoside inhibitors and NS3 protease inhibitors.
Tako sofosbuvir kot velpatasvir sta bila povsem aktivna pri substitucijah, povezanih z odpornostjo na druga zdravila z direktnim delovanjem na viruse z različnimi mehanizmi delovanja, kot so nenukleozidni zaviralci NS5B in zaviralci proteaze NS3.
Both sows and gilts (and their piglets) were investigated in these studies.
V njih so cepivo preučevali na svinjah in mladicah.
Both studies compared Intelence with placebo (a dummy treatment), when they were taken with boosted darunavir (a protease inhibitor) and at least two other anti-HIV medicines that were chosen for each patient as they had the best chances of reducing the levels of HIV in the blood.
V obeh študijah so zdravilo Intelence primerjali s placebom (zdravilom brez zdravilne učinkovine), pri čemer so bolniki oba jemali skupaj z okrepljenim darunavirjem (zaviralcem proteaze) in z vsaj dvema drugima zdraviloma proti virusu HIV, izbranima za vsakega posameznega bolnika posebej, s čimer se je doseglo optimalno zmanjšanje ravni virusa HIV v krvi.
Both studies compared the effects of Aptivus with those of another protease inhibitor that was chosen on the basis of the patient’s previous treatments and predicted response.
V obeh študijah so primerjali učinke zdravila Aptivus z učinki drugega zaviralca proteaze, izbranega na podlagi bolnikovih predhodnih zdravljenj in predvidenega odziva.
Both studies compared the effects of Fuzeon, in combination with ‘optimised background therapy’ (a combination of other antiviral medicines chosen for each patient as they had the best chances of reducing the levels of HIV in the blood), compared with optimised background therapy without Fuzeon.
V obeh študijah so učinke zdravila Fuzeon v kombinaciji z „optimiziranim osnovnim zdravljenjem“ (kombinacijo drugih protivirusnih zdravil, izbranih za posameznega bolnika, ki je obetala največjo verjetnost za zmanjšanje koncentracije virusa HIV v krvi) primerjali z optimiziranim osnovnim zdravljenjem brez zdravila Fuzeon.
Both studies compared Vidaza with conventional care (treatment chosen for each patient based on local practice and the patient’s condition).
V obeh študijah so zdravilo Vidaza primerjali z običajno oskrbo (zdravljenjem, ki je za vsakega bolnika izbrano na podlagi lokalne prakse in njegovega zdravstvenega stanja).
Both studies enrolled adult patients ( 18 years) who had a history of receiving Botulinum Toxin Type A. The first study enrolled patients who were clinically resistant to type A toxin (A-non responders), confirmed by a Frontalis Type A test.
Obe študiji sta vključevali odrasle bolnike (stari 18 let in več), ki so v preteklosti prejemali botulinski toksin vrste A. V prvi študiji so vključili bolnike, ki so bili klinično rezistentni na toksin vrste A (A-nedovzetni), kar je bilo potrjeno s testom vrste A Frontalis.
Both studies included patients who had experienced ≥2 relapses in the prior 2 years or ≥1 relapse during the prior year.
V obe študiji so vključili bolnike, ki so imeli v predhodnih 2 letih ≥2 zagona ali v predhodnem letu ≥1 zagon.
Both studies showed the vaccine to be effective in reducing death.
Obe študiji sta dokazali, da je cepivo učinkovito pri zmanjševanju poginov.
Both studies were powered and stratified so that at least 50% of patients randomized to each treatment arm met baseline criteria to be categorized as a laxative inadequate responder (LIR).
Izračun moči in stratifikacija obeh študij sta bila takšna, da je vsaj 50 % bolnikov, randomiziranih v vsako terapevtsko skupino, izpolnjevalo merila za uvrstitev med bolnike z nezadostnim odzivom na odvajala.
Both studies were randomised, parallel-group, double-blind, multinational trials in patients with symptomatic proximal DVT or symptomatic PE.
Študiji sta bili randomizirani, dvojno slepi, mednarodni preskušanji z vzporednimi skupinami pri bolnikih s simptomatsko proksimalno GVT ali simptomatsko PE.
both studies, the main measure of effectiveness was the number of patients with a complete or partial response to treatment.
V obeh študijah je bilo glavno merilo učinkovitosti število bolnikov s popolnim ali delnim odzivom na zdravljenje.
Both substances are protease inhibitors: they block an enzyme called protease that is involved in the reproduction of HIV.
Obe učinkovini sta zaviralca proteaz: zavirata encim, imenovan proteaza, ki sodeluje pri razmnoževanju virusa HIV.
Both the 0.5 ml and 1 ml vials contain an overfill to allow the withdrawal of 50 mg or 100 mg respectively.
Obe viali, 0,5 ml in 1 ml, vsebujeta presežek za zagotovitev odvzema 50 mg ali 100 mg.
Both the 0.5 ml and 1 ml vials contain an overfill to allow the withdrawal of 50 mg or 100 mg, respectively.
Obe viali, 0,5 ml in 1 ml, vsebujeta presežek za zagotovitev odvzema 50 mg oziroma 100 mg.
Both the 2.5 mg twice daily and the 5 mg twice daily regimens of rivaroxaban were effective in further reducing the incidence of CV events on a background of standard antiplatelet care.
Poleg standardnega antiagregacijskega zdravljenja sta bila oba režima 2,5 mg rivaroksabana dvakrat na dan kot 5 mg rivaroksabana dvakrat na dan učinkovita pri nadaljnjem zmanjševanju incidence kardiovaskularnih dogodkov.
Both the events of hypertrophic scarring were medically confirmed; in one case the scar was persistent after 12 months.
V nekaterih primerih so ostale spremembe nespremenjene več kot eno leto po zdravljenju.
Both the invented name Kadcyla and its full non-proprietary name (trastuzumab emtansine) should be used and confirmed when prescribing, preparing the infusion solution and administering Kadcyla to patients.
Pri predpisovanju, pripravi infuzijske raztopine in aplikaciji se mora uporabljati oziroma potrjevati zaščiteno ime Kadcyla in celotno nezaščiteno ime (trastuzumab emtanzin).
Both the liver and the kidney have been shown to metabolise IGF-1.
IGF-1 se presnavlja v jetrih in v ledvicah.
Both the R- and S-isomer of omeprazole have similar pharmacodynamic activity.
Farmakodinamično delovanje R- in S-izomera omeprazola je podobno.
Both treatment groups received Vitamin K antagonist therapy usually initiated within 72 hours after the first study drug administration and continued for 90 ± 7 days, with regular dose adjustments to achieve an INR of 2-3.
Obe zdravljeni skupini sta dobivali terapijo z antagonistom vitamina K, uvedeno prej kot 72 ur po prvi aplikaciji proučevanega zdravila, ki se je nadaljevala 90 ± 7 dni, z rednimi popravki odmerka, da so dosegli INR 2-3.
Both treatments reduced flea and tick numbers to almost zero by the end of the study period.
Obe zdravljenji sta do konca trajanja študije zmanjšali število bolh in klopov na skoraj nič.
Both vaccines contain very small amounts of a protein (albumin) that is used in the manufacturing process.
Obe cepivi vsebujeta zelo majhne količine beljakovine (albumina), ki se uporablja v proizvodnem postopku.
Both vardenafil and sildenafil showed an increase of Fridericia QTc effect of 4 msec (vardenafil) and 5 msec (sildenafil) when compared to either drug alone.
Pri obeh kombinacijah, z vardenafilom in sildenafilom se je doba QTc (Fridericia) podaljšala; za 4 msec pri vardenafilu in 5 msec pri sildenafilu v primerjavi s posameznim zdravilom.
both Week 8 and Week 30)a 5.3%
(remisija tako v 8. tednu kot v
bottle
plastenka
BOTTLE
PRIMARNI OVOJNINI
Bottle
STEKLENIČKA
bottle
teklenico
Bottle
Viala
Bottle
Vsebnik
Bottle (10 ml and 50 ml)
Steklenica (10 ml in 50 ml)
Bottle (30 ml)
Steklenička (30 ml)
Bottle (40 ml)
Steklenička (40 ml)
Bottle (60 ml)
Steklenička (60 ml)
bottle (amber glass)
steklenica (temno obarvano steklo)
bottle (amber glass)
teklenica (temno obarvano
BOTTLE (Bottle label)
STEKLENIČKA (Nalepka na steklenički)
Bottle (clear Type I glass) with an attached metering pump incorporating an audible dose counter and a protective cap (solid white cap for the 2 spray and translucent cap for the 8 spray).
Steklenica (prozorno steklo tipa I) z dodano črpalko za odmerjanje, ki vključuje slišen števec odmerkov in zaščitno zaporko (neprosojna bela zaporka za steklenico z 2 vpihoma in prosojna zaporka za steklenico z 8 vpihi).
Bottle (Glass with measuring syringe (LDPE)
Stekleno vialo + odmerno brizgo
bottle (glass)
(steklo) steklenica
Bottle (glass)
Plastenka (PP)
Bottle (glass)
Plastenka (steklo)
bottle (glass)
steklenica
Bottle (glass)
steklenica (glass)
bottle (glass)
steklenica (steklena)
bottle (glass)
steklenica (steklo)
bottle (glass)
Steklenička
bottle (glass)
steklenička (sklenená)
bottle (glass)
steklenička (steklena)
Bottle (glass)
steklenička (steklo)
bottle (glass)
Steklenička (steko)
bottle (glass)
stekleničke (iz stekla)
Bottle (glass)
teklenica (glass)
bottle (glass)
teklenica (steklo)
bottle (glass)
vsebnik (steklo)
bottle (glass) + spoon
teklenica (steklo) +
bottle (glass) + syringe
teklenica (steklo) +
Bottle (glass) in plastic
Steklenica v plastičnem
bottle (glass);
teklenička (steklo);
Bottle (HDPE)
Bela steklenica (HDPE)
bottle (HDPE)
HDPE plastenka
Bottle (HDPE)
HDPE plastenko
bottle (HDPE)
HDPE vsebnik
bottle (HDPE)
plastenka
Bottle (HDPE)
plastenka (HDP)
bottle (HDPE)
Plastenka (HDPE)
bottle (HDPE)
plastenka(HDPE)
bottle (HDPE)
Plastenke iz polietilena visoke gostote
bottle (HDPE)
plastični vsebnik
Bottle (HDPE)
Polietilenska plastenka
Bottle (HDPE)
Steklenica
Bottle (HDPE)
Steklenica (polietilen velike gostote)
Bottle (HDPE)
Steklenicka (HDPE)
Bottle (HDPE)
Steklenika (HDPE)
bottle (HDPE)
steklenička
bottle (HDPE)
Steklenička (HDPE)
bottle (HDPE)
Steklenička (PET)
bottle (HDPE)
teklenica
Bottle (HDPE)
Vsebnik (HDPE)
bottle (HDPE)
vsebnik za tablete (HDPE)
bottle (HDPE) multi- layer
plastenka (HDPE) večplastna
Bottle (HDPE) with child- resistant closure (PP)
Steklenica (HDPE) z zamaškom varnim za otroke (PP)
bottle (HDPE) with child-resistant closure
steklenička (HDPE) z načinom zapiranja, varnim za otroke
Bottle (HDPE) with measuring syringe (LDPE)
Polietilensko vialo visoke gostote + odmerno brizgo
bottle (HDPE) with screw cap
steklenička (HDPE) z vrtljivim pokrovčkom
bottle (HDPE) without outer carton
Plastenke iz polietilena visoke gostote brez zunanje ovojnine
Bottle (HDPE/alu) Bottle (HDPE/alu)
Steklenička (HDPE/alu)
Bottle (HDPE/PP)
Plastenka (HDPE/PP)
BOTTLE (LABEL)
VSEBNIK (NALEPKA)
Bottle (LDPE)
kapalni vsebnik (LDPE)
Bottle (LDPE)
Plastenka (LDPE)
Bottle (LDPE)
steklenička (LDPE)
Bottle (LDPE)
vsebnik (LDPE)
Bottle (LDPE) oval
kapalni vsebnik (LDPE), ovalni
Bottle (LDPE) round
kapalni vsebnik (LDPE), okrogli
Bottle (LPDE)
steklenička
bottle (PE)
steklenica (PE)
Bottle (PET)
Plastenka (PET)
Bottle (PET)
plastenko PET
bottle (PET)
Steklenica (PET)
bottle (plastic)
plastenka
bottle (plastic)
plastenka (plastika)
Bottle (plastic)
plastenka (plastična)
bottle (plastic)
teklenica
Bottle (polyethylene bottle with polypropylene closure)
Plastični vsebnik (polietilenski) s polipropilenskim pokrovom
Bottle (polyethylene bottle with polypropylene closure)
Plastični vsebnik (polietilenski) s polipropilenskim pokrovom)
Bottle (Polyethylene)
Pakiranje
Bottle (Polyethylene)
plastenka (polietilen)
Bottle (polyethylene)
polietilenska plastenka
Bottle (polypropylene)
(polipropilen)
bottle (polypropylene)
kapalni vsebnik (polipropilen)
Bottle (polypropylene)
Steklenička
Bottle (polypropylene)
Steklenička (polipropilen)
bottle (PP)
(alu/alu) plastenka (PP)
bottle (PP)
(alu/alu) plastenka(PP)
bottle (PP)
kapalni vsebnik (PP)
Bottle (PP)
Plastenka (PP)
Bottle (PP)
Steklenička (PP)
Bottle + syringe
steklenička + merilna brizga
Bottle 17.5 mL and 35.1 mL
Plastenka 17.5 in 35.1 ml
Bottle 8.8 mL
Plastenka 8.8 ml
BOTTLE AND CARTON LABELLING
OZNAKE NA PLASTIČNEM VSEBNIKU IN ŠKATLI
BOTTLE AND CARTON LABELLING
OZNAČEVANJE NA PLASTENKI IN ŠKATLI
BOTTLE AND CARTON LABELLING
OZNAČEVANJE NA VSEBNIKU IN ŠKATLI
BOTTLE CARTON
ŠKATLA S PLASTENKO
BOTTLE CARTON
ŠKATLA ZA STEKLENIČKO
BOTTLE CARTON
ŠKATLA ZA VSEBNIK
BOTTLE CARTON (60 hard capsules) – NUEDEXTA 15 mg/9 mg capsules
ŠKATLA ZA PLASTENKO (60 trdih kapsul) – NUEDEXTA 15 mg/9 mg kapsule
BOTTLE CARTON (60 hard capsules) – NUEDEXTA 23 mg/9 mg capsules
ŠKATLA ZA PLASTENKO (60 trdih kapsul) – NUEDEXTA 23 mg/9 mg kapsule
BOTTLE CARTON (INDIVIDUAL PACKS ONLY)
ŠKATLA ZA PLASTENKO (SAMO POSAMIČNA PAKIRANJA)
BOTTLE CARTON (MULTIPACKS ONLY – WITH BLUE BOX)
ŠKATLA ZA PLASTENKO (SAMO SKUPNA PAKIRANJA – Z »BLUE BOX«)
BOTTLE CARTON FOR 30 MG HARD GASTRO RESISTANT CAPSULES
ŠKATLA ZA PLASTENKO ZA 30 MG TRDE GASTROREZISTENTNE KAPSULE
BOTTLE CARTON FOR 60 MG HARD GASTRO RESISTANT CAPSULES
ŠKATLA ZA PLASTENKO ZA 60 MG TRDE GASTROREZISTENTNE KAPSULE
BOTTLE CARTON FOR ORAL SOLUTION
ŠKATLA ZA PLASTENKO S PERORALNO RAZTOPINO
BOTTLE CARTON LABEL
ŠKATLA S PLASTENKO
BOTTLE CARTON X 30 FILM-COATED TABLETS (300 mg )
ŠKATLA ZA PLASTENKO S 30 FILMSKO OBLOŽENIMI TABLETAMI (300 mg)
BOTTLE CARTON x 60 FILM COATED TABLETS
ŠKATLICA ZA PLASTENKO S 60 FILMSKO OBLOŽENIMI TABLETAMI
BOTTLE CARTON X 60 FILM-COATED TABLETS (150 mg)
ŠKATLA ZA PLASTENKO S 60 FILMSKO OBLOŽENIMI TABLETAMI (150 mg)
bottle closed
teklenička